{"id":"W4387526419","doi":"10.1158/1078-0432.ccr-23-2005","title":"A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"BioPhage Pharma (Canada)","funders":"Stand Up To Cancer; Genentech; Ipsen; Seagen; National Cancer Institute; Bayer; Servier; Pfizer; Incyte; Moderna; Revolution Medicines; Merck KGaA; Boston Scientific Corporation; National Institutes of Health; Helsinn; Bristol-Myers Squibb; Dana-Farber/Harvard Cancer Center; Pharmavite; American Association for Cancer Research; Amgen; EMD Serono; Lustgarten Foundation; Hale Family Center for Pancreatic Cancer Research; AstraZeneca; Eli Lilly and Company; Celgene","keywords":"Gemcitabine; Medicine; Internal medicine; Oncology; Cohort; Biomarker; Adverse effect; Pancreatic cancer; Cancer; Gastroenterology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002308185,0.001363353,0.001537659,0.0003584482,0.0006050475,0.0008486455,0.0007643015,0.0007670822,0.001889452],"category_scores_gemma":[0.0009766453,0.0004753502,0.001170599,0.0003670587,0.0008798497,0.00082221,0.0005643151,0.002972895,0.0005472142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00121013,"about_ca_system_score_gemma":0.001803698,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009601503,"about_ca_topic_score_gemma":0.00236987,"domain_scores_codex":[0.9993673,0.0002777259,0.00002826867,0.0001296001,0.00008235832,0.000114802],"domain_scores_gemma":[0.9989705,0.0001268255,0.0001806874,0.0001703153,0.00007617848,0.0004755406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5707792,0.1160796,0.1015021,0.0003738717,0.001807768,0.0008524173,0.0006227622,0.003139332,0.1040066,0.0002176459,0.00547823,0.09514046],"study_design_scores_gemma":[0.1830111,0.6927147,0.1023726,0.00003144775,0.0009009126,0.001140456,0.0001806557,0.001936112,0.0130022,0.0001629497,0.004488836,0.00005803572],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971254,0.0003583851,0.0002929627,0.0001110311,0.00002665585,0.001007168,0.0005252615,0.00002888123,0.0005241426],"genre_scores_gemma":[0.9923573,0.0003692782,0.001137465,0.0003528268,0.00008387023,0.00128722,0.003284574,0.00002197331,0.001105585],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002308185,"threshold_uncertainty_score":0.01220703,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1727717262365048,"score_gpt":0.5296481500083204,"score_spread":0.3568764237718157,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}